The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.
You may also be interested in...
Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.
Patent Reform Clears House, But Provisions On PTO Fees, Patent Term Extension Differ From Senate
The Medicines Company and the Appropriations Committee score victories as the House clears the bill by a vote of 304 to 117.
Patent Reform Clears House, But Provisions On PTO Fees, Patent Term Extension Differ From Senate
The Medicines Company and the Appropriations Committee score victories as the House clears the bill by a vote of 304 to 117.